Literature DB >> 1682363

Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis.

C L Finstad1, B W Yin, C M Gordon, M G Federici, S Welt, K O Lloyd.   

Abstract

Monoclonal antibodies (MAb) C219 and JSB-1 have been used extensively in the analysis of P-glycoprotein expression in normal and malignant tissues. This study demonstrates that some commercial lots of these MAb, even those supplied as purified immunoglobulins, contain contaminating anti-A blood group antibodies. In both sources of reagent, the antibody was specific for a particular A structure, known as repetitive or Type 3 A. These observations may account for earlier studies showing polymorphic variation in P-glycoprotein expression in epithelial tissues and an apparent correlation with the A blood type of the donor. Such reactivity can be eliminated by absorption of anti-P-glycoprotein reagents with A erythrocytes. These data re-emphasize the importance of evaluating MAb samples for unsuspected contaminating antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682363     DOI: 10.1177/39.12.1682363

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  16 in total

1.  Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons.

Authors:  Leigh Zerboni; Raymond A Sobel; Michelle Lai; Richard Triglia; Megan Steain; Allison Abendroth; Ann Arvin
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Recombinant monoclonal antibody recognizes a unique epitope on varicella-zoster virus immediate-early 63 protein.

Authors:  Niklaus H Mueller; Nathan L Bos; Scott Seitz; Mary Wellish; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.

Authors:  K Tóth; M M Vaughan; N S Peress; H K Slocum; Y M Rustum
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

4.  Establishment of a transplantable carcinoma arising from the intrahepatic bile duct in Syrian golden hamsters.

Authors:  T Fukahori; T Tomioka; K Inoue; Y Tajima; T Tsunoda; T Kanematsu
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Flow cytometric analysis of P-glycoprotein in normal and leukemic cells.

Authors:  M I Tiirikainen; M T Syrjälä; S E Jansson; T Krusius
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

6.  Presence of a neo-epitope and absence of amyloid beta and tau protein in degenerative hippocampal granules of aged mice.

Authors:  Gemma Manich; Jaume del Valle; Itsaso Cabezón; Antoni Camins; Mercè Pallàs; Carme Pelegrí; Jordi Vilaplana
Journal:  Age (Dordr)       Date:  2013-07-19

7.  New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues.

Authors:  K Tóth; M M Vaughan; H K Slocum; M A Arredondo; H Takita; R M Baker; Y M Rustum
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

8.  Expression of mdr1 gene in human breast primary tumors and metastases.

Authors:  E Hennequin; C Delvincourt; C Pourny; J C Jardillier
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 9.  Antibodies in the study of multiple drug resistance.

Authors:  Y Heike; T Tsuruo
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein.

Authors:  L Jetté; J F Pouliot; G F Murphy; R Béliveau
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.